CY1122900T1 - Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii και μεθοδοι χρησης αυτων - Google Patents

Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii και μεθοδοι χρησης αυτων

Info

Publication number
CY1122900T1
CY1122900T1 CY20191100325T CY191100325T CY1122900T1 CY 1122900 T1 CY1122900 T1 CY 1122900T1 CY 20191100325 T CY20191100325 T CY 20191100325T CY 191100325 T CY191100325 T CY 191100325T CY 1122900 T1 CY1122900 T1 CY 1122900T1
Authority
CY
Cyprus
Prior art keywords
chimeric
methods
factor viii
hybrid polypeptides
hybrid factor
Prior art date
Application number
CY20191100325T
Other languages
English (en)
Inventor
Jennifer A. Dumont
Susan Low
Alan J. Bitonti
Glenn Pierce
Alvin Luk
Haiyan Jiang
Byron Mckinney
Matt Ottmer
Jurg Sommer
Karen Nugent
Lian Li
Robert Peters
Original Assignee
Bioverativ Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc. filed Critical Bioverativ Therapeutics Inc.
Publication of CY1122900T1 publication Critical patent/CY1122900T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μεθόδους χορήγησης Παράγοντα VIII (επεξεργασμένος FVIII, FVIII απλής αλυσίδας, ή ένα συνδυασμό αυτών), μεθόδους χορήγησης χιμαιρικών και υβριδικών πολυπεπτιδίων που περιέχουν Παράγοντα VIII, χιμαιρικών και υβριδικών πολυπεπτιδίων που περιέχουν VIII, πολυνουκλεοτιδίων που κωδικοποιούν τέτοια χιμαιρικά και υβριδικά πολυπεπτίδια, κυττάρων που περιέχουν τέτοια πολυνουκλεοτίδια, και μεθόδους παραγωγής τέτοιων χιμαιρικών και υβριδικών πολυπεπτιδίων χρησιμοποιώντας τέτοια κύτταρα.
CY20191100325T 2011-07-08 2019-03-19 Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii και μεθοδοι χρησης αυτων CY1122900T1 (el)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201161506015P 2011-07-08 2011-07-08
US201161522647P 2011-08-11 2011-08-11
US201161541561P 2011-09-30 2011-09-30
US201161569158P 2011-12-09 2011-12-09
US201261586443P 2012-01-13 2012-01-13
US201261622789P 2012-04-11 2012-04-11
US201261657641P 2012-06-08 2012-06-08
PCT/US2012/045784 WO2013009627A2 (en) 2011-07-08 2012-07-06 Factor viii chimeric and hybrid polypeptides, and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1122900T1 true CY1122900T1 (el) 2021-05-05

Family

ID=47506823

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100325T CY1122900T1 (el) 2011-07-08 2019-03-19 Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii και μεθοδοι χρησης αυτων

Country Status (27)

Country Link
US (3) US10010622B2 (el)
EP (3) EP4169525A1 (el)
JP (5) JP2014522838A (el)
KR (2) KR102110736B1 (el)
CN (2) CN103796670A (el)
AR (1) AR087091A1 (el)
AU (3) AU2012282875B2 (el)
BR (1) BR112014000466A2 (el)
CA (1) CA2841066C (el)
CL (1) CL2014000024A1 (el)
CO (1) CO6940381A2 (el)
CY (1) CY1122900T1 (el)
DK (2) DK2729161T3 (el)
EA (1) EA029045B1 (el)
ES (2) ES2913994T3 (el)
HR (2) HRP20220639T1 (el)
HU (1) HUE043763T2 (el)
IL (2) IL230333B (el)
LT (2) LT3513804T (el)
MX (1) MX350581B (el)
MY (1) MY180714A (el)
PL (2) PL2729161T3 (el)
PT (2) PT3513804T (el)
RS (2) RS58578B1 (el)
SI (2) SI3513804T1 (el)
TW (3) TWI687226B (el)
WO (1) WO2013009627A2 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE497783T1 (de) * 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
US8637007B2 (en) 2006-12-15 2014-01-28 Baxter International Inc. Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2533619C2 (ru) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Гликополисиалирование белков, не являющихся белками свертывания крови
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5908401B2 (ja) 2009-07-27 2016-04-26 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 血液凝固タンパク質複合体
PL3326643T3 (pl) 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
DK2729161T3 (en) * 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF
RS57936B1 (sr) * 2012-01-12 2019-01-31 Bioverativ Therapeutics Inc Smanjenje imunogenosti na faktor viii kod osoba na terapiji faktorom viii
WO2013155324A1 (en) 2012-04-11 2013-10-17 Biogen Idec Ma Inc. Methods of detecting glycosaminoglycans
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc CHIMERIC COAGULATION FACTORS
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
EP3446700A1 (en) * 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
LT3889173T (lt) * 2013-02-15 2023-10-10 Bioverativ Therapeutics Inc. Optimizuotas viii faktoriaus genas
EP4122487A1 (en) * 2013-03-15 2023-01-25 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
US9234757B2 (en) 2013-11-29 2016-01-12 Fedex Corporate Services, Inc. Determining node location using a variable power characteristic of a node in a wireless node network
US10453023B2 (en) 2014-05-28 2019-10-22 Fedex Corporate Services, Inc. Methods and node apparatus for adaptive node communication within a wireless node network
US11238397B2 (en) 2015-02-09 2022-02-01 Fedex Corporate Services, Inc. Methods, apparatus, and systems for generating a corrective pickup notification for a shipped item using a mobile master node
US10057133B2 (en) 2015-07-08 2018-08-21 Fedex Corporate Services, Inc. Systems, apparatus, and methods of enhanced monitoring for an event candidate associated with cycling power of an ID node within a wireless node network
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
WO2017165011A1 (en) 2016-03-23 2017-09-28 Fedex Corporate Services, Inc. Systems, apparatus, and methods for self-adjusting a broadcast setting of a node in a wireless node network
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CA3044838A1 (en) * 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
EP3706720A4 (en) 2017-11-07 2021-08-18 Rani Therapeutics, LLC COAGULATION FACTOR PREPARATIONS TO BE ADMINISTERED INTO INTESTINAL TRACT TISSUE BY MEANS OF A MEDICINAL DELIVERY DEVICE
US12098179B2 (en) 2018-03-16 2024-09-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175381A1 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175380A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
EP3773674A4 (en) * 2018-03-28 2022-05-25 Orionis Biosciences, Inc. BIFUNCTIONAL PROTEINS AND THEIR CONSTRUCTION
TW202015723A (zh) * 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
WO2020227162A1 (en) * 2019-05-03 2020-11-12 Rani Therapeutics, Llc Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device
MX2021015897A (es) 2019-06-19 2022-04-18 Bioverativ Therapeutics Inc Factor viii recombinante-fc para el tratamiento de la hemofilia y la densidad mineral osea baja.
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
WO1986006101A1 (en) 1985-04-12 1986-10-23 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE69029799T2 (de) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
DE60122286T2 (de) 2000-02-11 2007-08-02 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
WO2003031598A2 (en) * 2001-10-05 2003-04-17 Emory University Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
DK1463751T3 (da) 2001-12-21 2013-08-26 Human Genome Sciences Inc Albuminfusionsproteiner.
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
ATE497783T1 (de) 2003-05-06 2011-02-15 Syntonix Pharmaceuticals Inc Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
SI3130601T1 (sl) 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
SG123635A1 (en) 2004-12-28 2006-07-26 Nanoscience Innovation Pte Ltd Nanostructured zinc oxide and a method of producing the same
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2007103515A2 (en) 2006-03-06 2007-09-13 Amunix, Inc. Unstructured recombinant polymers and uses thereof
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
DK2369005T3 (da) 2007-06-21 2013-06-24 Univ Muenchen Tech Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
NZ606427A (en) 2009-02-03 2014-10-31 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
PL3326643T3 (pl) * 2009-12-06 2021-10-25 Bioverativ Therapeutics Inc. Chimeryczne i hybrydowe polipeptydy czynnika VIII-FC oraz sposoby ich zastosowania
EP3508573A1 (en) * 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
SG186875A1 (en) 2010-07-09 2013-02-28 Biogen Idec Hemophilia Inc Chimeric clotting factors
DK2729161T3 (en) * 2011-07-08 2019-04-08 Bioverativ Therapeutics Inc FACTOR VIII CHEMICAL AND HYBRID POLYPEPTIDES AND PROCEDURES FOR USE THEREOF

Also Published As

Publication number Publication date
JP2023134851A (ja) 2023-09-27
PT2729161T (pt) 2019-04-01
AU2018202936B2 (en) 2020-07-02
EA201490039A1 (ru) 2014-06-30
CN107261122A (zh) 2017-10-20
CA2841066C (en) 2023-09-26
KR101829603B1 (ko) 2018-02-19
US20210220476A1 (en) 2021-07-22
MX2014000202A (es) 2014-10-06
ES2722209T3 (es) 2019-08-08
EP2729161A4 (en) 2015-06-24
AR087091A1 (es) 2014-02-12
CN103796670A (zh) 2014-05-14
IL271870A (en) 2020-02-27
AU2012282875B2 (en) 2016-04-21
IL271870B (en) 2022-04-01
JP2017088623A (ja) 2017-05-25
MX350581B (es) 2017-09-11
DK2729161T3 (en) 2019-04-08
HRP20220639T1 (hr) 2022-07-08
RS58578B1 (sr) 2019-05-31
KR20180020305A (ko) 2018-02-27
JP7273487B2 (ja) 2023-05-15
TW201315480A (zh) 2013-04-16
WO2013009627A3 (en) 2013-03-07
JP2019048877A (ja) 2019-03-28
US20140294821A1 (en) 2014-10-02
RS63241B1 (sr) 2022-06-30
AU2018202936A1 (en) 2018-05-17
EP2729161B1 (en) 2018-12-19
PT3513804T (pt) 2022-06-02
LT2729161T (lt) 2019-04-10
AU2012282875A1 (en) 2013-05-02
HUE043763T2 (hu) 2019-09-30
CL2014000024A1 (es) 2014-11-21
HRP20190535T1 (hr) 2019-05-17
SI2729161T1 (sl) 2019-05-31
AU2016204986B2 (en) 2018-05-10
WO2013009627A2 (en) 2013-01-17
EP3513804A1 (en) 2019-07-24
MY180714A (en) 2020-12-07
AU2016204986A1 (en) 2016-08-04
TW202042838A (zh) 2020-12-01
EP2729161A2 (en) 2014-05-14
KR102110736B1 (ko) 2020-05-14
EA029045B1 (ru) 2018-02-28
US20180360982A1 (en) 2018-12-20
IL230333B (en) 2020-05-31
SI3513804T1 (sl) 2022-07-29
TWI687226B (zh) 2020-03-11
TWI626947B (zh) 2018-06-21
LT3513804T (lt) 2022-05-25
US10881742B2 (en) 2021-01-05
NZ619438A (en) 2016-06-24
ES2913994T3 (es) 2022-06-07
JP2022003096A (ja) 2022-01-11
EP4169525A1 (en) 2023-04-26
PL3513804T3 (pl) 2022-07-11
KR20140066157A (ko) 2014-05-30
EP3513804B1 (en) 2022-03-23
CA2841066A1 (en) 2013-01-17
CO6940381A2 (es) 2014-05-09
BR112014000466A2 (pt) 2017-02-21
US10010622B2 (en) 2018-07-03
TWI764092B (zh) 2022-05-11
DK3513804T3 (da) 2022-06-20
JP2014522838A (ja) 2014-09-08
PL2729161T3 (pl) 2019-08-30
TW201822788A (zh) 2018-07-01

Similar Documents

Publication Publication Date Title
CY1122900T1 (el) Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii και μεθοδοι χρησης αυτων
CY1124888T1 (el) Χιμαιρικα και υβριδικα πολυπεπτιδια παραγοντα viii-fc και μεθοδοι χρησεως αυτων
CY1124176T1 (el) Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1122308T1 (el) St2l ανταγωνιστες και μεθοδοι χρησης
CY1123865T1 (el) Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
CY1117842T1 (el) Πολυπεπτιδια μεταλλαγμενης il-2
EP3286746A4 (en) Generating cryptographic function parameters from compact source code
EA201691078A1 (ru) Терапевтические пептиды
BR112016007805A2 (pt) receptor de antígeno quimérico
TR201900071T4 (tr) Kontrollü Over Stimülasyonuna Yönelik Bileşim
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
CY1124445T1 (el) Αντισωματα αντι-ccl17
MX361008B (es) Composiciones para el cuidado bucal que contienen polietilenglicol para estabilidad fisica.
IN2015DN03132A (el)
MX2016015008A (es) Composiciones para el cuidado bucal que contienen polietilenglicol para estabilidad fisica.
EA201491034A1 (ru) Экспрессионная кассета
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования